TSE:VBV VBI Vaccines - VBV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1,300 shsAverage Volume3,637 shsMarket CapitalizationC$308.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartInsider TradesHeadlinesSocial Media About VBI Vaccines (TSE:VBV) StockVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.Read More Receive VBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address VBV Stock News HeadlinesMarch 30, 2023 | nypost.comHow mRNA vaccines could target everything from cancer to the plagueMarch 28, 2023 | nbcnews.comModerna CEO grilled over plan to raise Covid vaccine price at Senate hearingApril 1, 2023 | Vantage Point (Ad)What’s At Stake In April is ShockingThe Fed will be meeting on a topic that could change trading forever, and the decision could come as soon as the end of April. But by taking the smartest approach now, you can help shield your assets and work toward your trading goals. Time, as always, is of the essence. Click on this link to see what you need to do right away. March 15, 2023 | usatoday.comPeople without insurance will still get free COVID vaccines once government's supply runs outMarch 13, 2023 | foxnews.comLA County eases COVID vaccine, testing restrictions as emergency declarations endFebruary 24, 2023 | cnbc.comFlu vaccine was 68% effective at preventing hospitalization in children but less protective for seniors this seasonFebruary 22, 2023 | reuters.comDevelop vaccines for all animal influenza strain, says incoming WHO chief scientistFebruary 22, 2023 | foxnews.comPrior COVID infection provides just as much protection as vaccines, new study findsApril 1, 2023 | Vantage Point (Ad)What’s At Stake In April is ShockingThe Fed will be meeting on a topic that could change trading forever, and the decision could come as soon as the end of April. But by taking the smartest approach now, you can help shield your assets and work toward your trading goals. Time, as always, is of the essence. Click on this link to see what you need to do right away. February 20, 2023 | usnews.comTwo Vaccines May Soon Shield Seniors Against RSVFebruary 15, 2023 | marketwatch.comThe Rise of Virus-like Particles (VLPs) Vaccine Market Research 2023-2029: Opportunities and ChallengesFebruary 11, 2023 | finance.yahoo.comAdvances and Growth Opportunities in RNA VaccinesFebruary 9, 2023 | usatoday.comFDA vaccine panel to consider annual COVID shots: What we knowJanuary 26, 2023 | foxnews.comYearly COVID vaccine as proposed by FDA? 'Cart before the horse,' says doctorJanuary 25, 2023 | abcnews.go.comFDA proposes most Americans receive one annual COVID vaccine, similar to fluJanuary 25, 2023 | reuters.comU.S. FDA proposes shift to annual COVID vaccine shotsJanuary 24, 2023 | cnet.comScientists Are Working on a COVID Vaccine You Can DrinkJanuary 22, 2023 | cnbc.comRSV vaccine: Moderna, Pfizer start a new FDA approval raceJanuary 16, 2023 | nypost.comCDC investigating whether Pfizer COVID vaccine increases stroke risk for people over 65January 14, 2023 | marketwatch.comVaccine Market Latest Trends 2023, Drivers, and Projections Report from 2023-2029| 101 Pages ReportJanuary 14, 2023 | nypost.comModerna under fire for 400% price hike of COVID vaccine: ‘Outrageous’January 13, 2023 | nypost.comPentagon ends COVID-19 vaccine mandate for US troopsJanuary 10, 2023 | marketwatch.comVLP Vaccines Market Global and Regional Analysis and Forecast 2028December 20, 2022 | msn.comLooking Into VBI Vaccines's Return On Capital EmployedNovember 10, 2022 | marketwatch.comVBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 15, 2022 | finance.yahoo.comFDA Approves Vaccine for Use During Third Trimester of Pregnancy to Prevent Whooping Cough in Infants Younger Than Two Months of AgeSeptember 15, 2022 | finance.yahoo.comVBI Vaccines Secures $100 Million Debt Facility From K2 HealthVenturesSee More Headlines Receive VBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE Industry N/A Sub-IndustryN/A SectorN/A Current SymbolTSE:VBV CUSIPN/A CIKN/A Webwww.vbivaccines.com Phone+1-617-8303031FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio14.29 Current Ratio2.64 Quick Ratio2.54 Sales & Book Value Annual SalesC$3.36 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.01 per share Price / BookN/AMiscellaneous Outstanding Shares64,079,000Free FloatN/AMarket CapC$308.86 million OptionableNot Optionable BetaN/A Key ExecutivesMr. Jeff R. Baxter (Age 57)CEO, Pres & Director Dr. David Evander Anderson Ph.D. (Age 48)Chief Scientific Officer Ms. Athena Kartsaklis (Age 53)Sr. VP of Fin., Principal Financial & Accounting Officer, Chief Compliance Officer Ms. Nell Beattie (Age 30)Chief Bus. Officer Dr. Francisco Diaz-Mitoma M.D. (Age 63)Ph.D., Chief Medical Officer VBV Stock - Frequently Asked Questions What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Teladoc Health (TDOC), PhaseBio Pharmaceuticals (PHAS), Amarin (AMRN), Adverum Biotechnologies (ADVM), Assertio (ASRT), Activision Blizzard (ATVI), Axsome Therapeutics (AXSM), Boeing (BA), Beyond Meat (BYND) and Cardlytics (CDLX). What is VBI Vaccines' stock symbol? VBI Vaccines trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VBV." How do I buy shares of VBI Vaccines? Shares of VBV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. How much money does VBI Vaccines make? VBI Vaccines (TSE:VBV) has a market capitalization of C$0.00 and generates C$3.36 million in revenue each year. How can I contact VBI Vaccines? VBI Vaccines' mailing address is 222 3rd St Ste 2241, CAMBRIDGE, MA 02142-1259, United States. The official website for the company is www.vbivaccines.com. The company can be reached via phone at +1-617-8303031. This page (TSE:VBV) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.